	US 12,213,992 B2
	Iron containing composition and use thereof
Robert Hider, Essex (GB); and Peter Geisser
Assigned to RENAPHARMA AB, Stockholm (SE)
Appl. No. 17/272,756
Filed by RENAPHARMA AB, Stockholm (SE)
PCT Filed Sep. 5, 2019, PCT No. PCT/EP2019/073637 § 371(c)(1), (2) Date Mar. 2, 2021, PCT Pub. No. WO2020/049074, PCT Pub. Date Mar. 12, 2020.
Claims priority of application No. 18192831 (EP), filed on Sep. 5, 2018.
Prior Publication US 2021/0205356 A1, Jul. 8, 2021
Int. Cl. A61K 33/26 (2006.01); A23D 7/005 (2006.01); A23L 33/12 (2016.01); A23L 33/165 (2016.01); A61K 9/10 (2006.01); A61K 31/23 (2006.01); A61P 7/06 (2006.01)

CPC A61K 33/26 (2013.01) [A23D 7/0053 (2013.01); A23L 33/12 (2016.08); A23L 33/165 (2016.08); A61K 9/10 (2013.01); A61K 31/23 (2013.01); A61P 7/06 (2018.01)]

15 Claims

1. A composition comprising

(i) an iron salt of a C12-C18 fatty acid;

(ii) a citric acid ester of mono- and/or diglyceride or a mixture of citric acid esters of mono- and/or diglyceride; and

(iii) a fatty acid or a salt thereof, or a mixture of fatty acids or fatty acid salts;

wherein the composition comprises from 5 to 50% by weight of component (i), from 50 to 95% by weight of component (ii), and up to 20% by weight of component (iii);

wherein the citric acid ester of mono- and/or diglyceride or mixture of citric acid esters of mono- and/or diglyceride comprises mono- and/or diglycerides of one or more C8-C24 fatty acids; and

wherein component (iii) comprises one or more C8-C24 fatty acids or salts thereof.